Mois : juin 2019

Marijuana and fertility, Sara Ilnitsky & Stan Van Uum, 2019

Marijuana and fertility Sara Ilnitsky MD, Stan Van Uum MD Canadian Medical Association Journal, 2019 June 10, 191, 23, E638. doi : 10.1503/cmaj.181577 CMAJ Podcasts: author interview at https://soundcloud.com/cmajpodcasts/181577-five   1 Tetrahydrocannabinol acts on the endocannabinoid system, which is ubiquitous in reproductive tissues Tetrahydrocannabinol, the active ingredient in marijuana, is a lipophilic compound with a prolonged half-life of 20–36 hours.1 Tetrahydrocannabinol activates the cannabinoid receptors, which are part of the endogenous endocannabinoid system. This system is found in the hypothalamus, pituitary and internal reproductive organs in both sexes.2,3 2 Marijuana use can decrease sperm count Smoking marijuana more than once weekly in the preceding 3 months (n = 130/1215) [...]

Lire la suite

The Endocannabinoid System : A New Treatment Target for Obsessive Compulsive Disorder ?, Reilly R. Kayser et al., 2019

The Endocannabinoid System : A New Treatment Target for Obsessive Compulsive Disorder ? Reilly R. Kayser, Ivar Snorrason, Margaret Haney, Francis S. Lee, and H. Blair Simpson1 Cannabis and Cannabinoid Research, 2019, Volume 4, Number 2, Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0049   Abstract Introduction : Obsessive-compulsive disorder (OCD) is a disabling illness that is associated with significant functional impairment. Although evidence-based pharmacotherapies exist, currently available medications are ineffective in some patients and may cause intolerable side effects in others. There is an urgent need for new treatments. Discussion : A growing body of basic and clinical research has showed that the endocannabinoid system(ECS) plays a role in [...]

Lire la suite

Cannabis Companies Push F.D.A. to Ease Rules on CBD Products, Sheila Kaplan, The New York Time, May 31, 2019

Cannabis Companies Push F.D.A. to Ease Rules on CBD Products By Sheila Kaplan The New York Time, May 31, 2019 CBD products have exploded in recent years, and are so numerous and varied as to include cheese pizza and fruit smoothies, like at this restaurant in Fort Lauderdale, Fla.CreditJennifer Lett/South Florida Sun-Sentinel, via Associated Press Image CBD products have exploded in recent years, and are so numerous and varied as to include cheese pizza and fruit smoothies, like at this restaurant in Fort Lauderdale, Fla.CreditCreditJennifer Lett/South Florida Sun-Sentinel, via Associated Press     WASHINGTON — It was Hempy Pet CBD Soft Chews, Mile High Labs and Women Grow, [...]

Lire la suite

Measuring Disturbance of the Endocannabinoid System in Psychosis. A Systematic Review and Meta-analysis, Amadeo Minichino et al., 2019

Measuring Disturbance of the Endocannabinoid System in Psychosis. A Systematic Review and Meta-analysis Amedeo Minichino, MD1; Morwenna Senior, MD1; Natascia Brondino, PhD2; et al Sam H Zhang, BA1; Beata R Godwlewska, PhD1; Philip W.J Burnet, PhD1; Andrea Cipriani, PhD1,3; Belinda R. Lennox, DM1 JAMA Psychiatry, Published online June 5, 2019. doi:10.1001/jamapsychiatry.2019.0970 Editorial : Pathophysiology of Endocannabinoid Signaling in Schizophrenia David W. Volk, MD, PhD; David A. Lewis, MD   Question  Is the endocannabinoid system abnormal in people with psychosis? Findings  In this systematic review and meta-analysis of 18 studies, a higher tone of the endocannabinoid system was observed in people with psychosis, a finding that was consistent across all stages of illness and independent of antipsychotic treatment and current cannabis use. This increased tone was [...]

Lire la suite

Au Canada, le cannabis comestible sera disponible à la vente en décembre, Le Monde, 15 juin 2019

Au Canada, le cannabis comestible sera disponible à la vente en décembre Le pays avait été en octobre le deuxième au monde, après l’Uruguay, à autoriser la vente libre de marijuana. Des règles strictes devront être respectées pour limiter l’attractivité des produits à base de cannabis auprès des jeunes. Le Monde avec AFP Publié , 15 juin 2019, aujourd’hui à 00h21, mis à jour à 11h11 Des cookies au cannabis dans un magasin éphèmère de Rome, en Italie, le 6 juin. ANDREW MEDICHINI / AP Des produits comestibles à base de cannabis seront vendus au Canada dès la mi-décembre, a annoncé, [...]

Lire la suite

Cannabis : interdiction au Canada d’en mettre dans la bière, les bonbons et les sucettes, Jean-Yves NAU, juin 2019

Cannabis : interdiction au Canada d’en mettre dans la bière, les bonbons et les sucettes Jean-Yves NAU Blog Journalisme et santé Publique, 15 juin 2019 Bonjour C’était écrit dans la légalisation du cannabis : son industrie du cannabis se professionnalise à grande vitesse 1, élargit sans cesse sa palette. Aujourd’hui l’Agence France Presse nous apprend que des « produits comestibles à base de cannabis » seront vendus au Canada dès la mi-décembre. Annonce officielle faite, vendredi 14 juin, par le gouvernement canadien. Qui précise que les « produits susceptibles de plaire aux enfants » (comme les bonbons ou les sucettes) ne pourront pas en contenir 2. Ces nouvelles dispositions  entreront en vigueur [...]

Lire la suite

Ketamine and Other NMDA Antagonists : Early Clinical Trials and Possible Mechanisms in Depression, D. Jeffrey Newport et al., 2015

Ketamine and Other NMDA Antagonists : Early Clinical Trials and Possible Mechanisms in Depression D. Jeffrey Newport, M.D., M.S., M.Div., Linda L. Carpenter, M.D., William M. McDonald, M.D., James B. Potash, M.D., M.P.H., Mauricio Tohen, M.D., Dr.P.H., M.B.A., Charles B. Nemeroff, M.D., Ph.D., The APA Council of Research Task Force on Novel Biomarkers and Treatments American Journal of Psychiatry, 2015, 172, 950–966 doi: 10.1176/appi.ajp.2015.15040465     Objective : The authors conducted a systematic review and meta-analysis of ketamine and other N-methyl-D-aspartate (NMDA) receptor antagonists in the treatment of major depression. Method : Searches of MEDLINE, PsycINFO, and other databases were conducted for placebo-controlled, double-blind, randomized clinical trials [...]

Lire la suite

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression. A Randomized Clinical Trial, Ella J. Daly et al., 2019

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression. A Randomized Clinical Trial Ella J. Daly, MD; Madhukar H. Trivedi, MD; Adam Janik, MD; Honglan Li, MD, PhD; Yun Zhang, PhD; Xiang Li, PhD; Rosanne Lane, MAS; Pilar Lim, PhD; Anna R. Duca, BSN; David Hough, MD; Michael E. Thase, MD; John Zajecka, MD; Andrew Winokur,MD, PhD; Ilona Divacka, MBA, MD; Andrea Fagiolini, MD; Wiesław J. Cubała, MD, PhD; István Bitter,MD, PhD; Pierre Blier,MD, PhD; Richard C. Shelton, MD; Patricio Molero,MD, PhD; Husseini Manji, MD;Wayne C. Drevets, MD; Jaskaran B. Singh, MD JAMA Psychiatry, [...]

Lire la suite

Lysergic acid diethylamide (LSD) for alcoholism : meta-analysis of randomized controlled trials, Teri S Krebs and Pål-Ørjan Johansen, 2012

Lysergic acid diethylamide (LSD) for alcoholism : meta-analysis of randomized controlled trials Teri S Krebs and Pål-Ørjan Johansen Journal of Psychopharmacology, 2012, 1–9 DOI: 10.1177/0269881112439253 jop.sagepub.com   Abstract Assessments of lysergic acid diethylamide (LSD) in the treatment of alcoholism have not been based on quantitative meta-analysis. Hence, we performed a meta-analysis of randomized controlled trials in order to evaluate the clinical efficacy of LSD in the treatment of alcoholism. Two reviewers independently extracted the data, pooling the effects using odds ratios (ORs) by a generic inverse variance, random effects model. We identified six eligible trials, including 536 participants. There was evidence for a beneficial effect of LSD [...]

Lire la suite

Cessation and reduction in alcohol consumption and misuse after psychedelic use, Albert Garcia-Romeu et al., 2019

Cessation and reduction in alcohol consumption and misuse after psychedelic use Albert Garcia-Romeu, Alan K Davis, Fire Erowid, Earth Erowid, Roland R Griffiths and Matthew W Johnson Journal of Psychopharmacology, 2019, 1–14 DOI: 10.1177/0269881119845793 journals.sagepub.com/home/jop   Abstract Background : Meta-analysis of randomized studies using lysergic acid diethylamide (LSD) for alcohol use disorder (AUD) showed large, significant effects for LSD efficacy compared to control conditions. Clinical studies suggest potential anti-addiction effects of LSD and mechanistically-related classic psychedelics for alcohol and other substance use disorders. Aims : To supplement clinical studies, reports of psychedelic use in naturalistic settings can provide further data regarding potential effects of psychedelics on alcohol use. Methods [...]

Lire la suite